Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

SciClone Announces $20 Million Stock Buyback

publication date: Oct 5, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
SciClone Pharma announced a share repurchase program of up to $20 million over the next 24 months. SciClone, headquartered in California, commercializes and markets Western drugs in China. In addition to boosting the company’s stock price, the repurchase program will partially offset the 8.3 million shares that may be offered by the previous owners of NovaMed, which SciClone acquired in April of this year. Despite its solid financial performance, SciClone's stock price remains low. More details....

Stock Symbol: (NSDQ: SCLN)

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners